箭头制药公司的首席执行官在公司出售了1%的股份,收入低于预期。 Arrowhead Pharmaceuticals' CEO sold a 1% stake in the company, amid lower-than-expected earnings.

Christopher Richard Anzone, 箭头制药公司首席执行官, 最近出售公司股票股份, 将他的股权减少了1%左右。 Christopher Richard Anzalone, CEO of Arrowhead Pharmaceuticals, recently sold shares of the company's stock, reducing his ownership by about 1%. 这些交易向证交会披露。 The transactions were disclosed to the SEC. 箭头制药公司的重点是开发治疗棘手疾病的药物,最近报告的季度收入低于预期。 Arrowhead Pharmaceuticals focuses on developing medicines for intractable diseases and recently reported lower-than-expected quarterly earnings. 该公司的市场上限为16.2亿美元,分析家预计该公司本年度的收益为每股2.42美元。 The company has a market cap of $1.62 billion and analysts expect it to post earnings of -$2.42 per share for the year.